Risk of Developing Hypertension by Daily Intake of Alcohol

Similar documents
슬라이드 1

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

심장2.PDF

전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II)

(Microsoft PowerPoint - S13-3_\261\350\273\363\307\366 [\310\243\310\257 \270\360\265\345])

저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비

Treatment and Role of Hormaonal Replaement Therapy

590호(01-11)

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr

(Microsoft PowerPoint - CXBTUEOAPVQY.ppt [\310\243\310\257 \270\360\265\345])

untitled

다이어트마침표_1부 :24 PM 페이지2 BMI지수의 진실 비만을 측정하는 대표적인 방법 가운데 하나가 BMI 지수다. BMI(Body Mass Index, 체질량지수)란 키와 몸무게를 이용하여 지방의 양을 추정하는 비만 측정법이다. 몸무게를 키의

Kjcg007( ).hwp

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

<30312DB0ADC0C7B7CF C3E1B0E8292DBABBB9AE2E687770>

DIABETES FACT SHEET IN KOREA 2012 SUMMARY About 3.2 million Korean people (10.1%) aged over 30 years or older had diabetes in Based on fasting g

서론 34 2

<3034C0D3BBF3C3E1B0E8C7D0BCFABCBCB9CCB3AA2E687770>

SG프랜-한남점 지노영수정.QXP

<30365F D BCBABFB5C1D85FC0FAC0DAB1B3C1A4B9DDBFB52E687770>

고혈압 어떻게 잘 진단하고, 치료할 것인가?

°íµî1´Ü¿ø

(Microsoft PowerPoint - KIPZMIFJVHEW [\310\243\310\257 \270\360\265\345])

<4D F736F F F696E74202D20B0B3BFF8C0C7BFACBCF6B0ADC1C220B0ADC0C7B7CF5FC1B6B1B8BFB5>

A 617

노영남

<4D F736F F F696E74202D20C1F5B7CAC1DFBDC9B0EDC7F7BED05FB1E8C7D1BCF65FBCADBFEFB4EBBAB4BFF82E BC8A3C8AF20B8F0B5E55D>

Part.1 당뇨병 관리의 첫걸음, 당뇨병 알기 당뇨병이란? 당뇨병의 원인은 무엇일까? 당뇨병의 종류 당뇨병의 증상과 진단 당뇨병의 치료 12 Part.2 당뇨병과 식사관리 당뇨병과 올바른 식사 23 2.

페링야간뇨소책자-내지-16

고혈압 어떻게 잘 진단하고, 치료할 것인가?

<B1DDBFACC5ACB8AEB4D02DC6EDC1FD28C3D6C1BE292DB1B3C1A4BFCFB7E128BABCB5E5BBE8C1A6292E687770>

2009년 2학년 2학기 혈액종양학 강의평가


< B3E220BCF6C1B7B1B8BAB4C1F6C4A72D56312E687770>

부속

Microsoft PowerPoint - NPDZIIEIJWUR.pptx

Microvascular Angina Data From Korean Women's Chest Pain Registry

한국성인에서초기황반변성질환과 연관된위험요인연구

확장기혈압의증가와혈관질환의증가 2. 수축기혈압의증가와혈관질환발생과의관계 P i P s P d t p t r Flow Pressure Fig. 1. Amplitude and timing of wave reflection. Kor J Cerebrovascula

<303920BFF8C0FA B1E8B5BFB9CE2DC0CCB8EDBFEB35302D35372E687770>

(한마음)


e01.PDF

슬라이드 1

14년5, 6월 한마음

00약제부봄호c03逞풚

16(1)-9(국문)(p.46-51).fm

Microsoft PowerPoint Free Papers (Abstracts)12.ppt


Microsoft PowerPoint - CNVZNGWAIYSE.pptx

나주-02월-3,000

김범수

<30375F32342D DBFF8C0FA2DC0E5C0CCBCB12EB1E8B1BABCF85FC0FAC0DAB1B3C1A4B9DDBFB52E687770>

388 The Korean Journal of Hepatology : Vol. 6. No COMMENT 1. (dysplastic nodule) (adenomatous hyperplasia, AH), (macroregenerative nodule, MR

056~


<5B31362E30332E31315D20C5EBC7D5B0C7B0ADC1F5C1F8BBE7BEF720BEC8B3BB2DB1DDBFAC2E687770>

<303320C1BEBCB C3D6C8ABBBF32DB1E8BCF6BFCF292E687770>

오늘말씀드릴내용 특징 자연경과및단계 단백뇨의기준, 선별검사 치료 증례

<B0E6C8F1B4EBB3BBB0FA20C0D3BBF3B0ADC1C E687770>

Review 1 뇌혈관질환 전문병원 지 정기념 <2012 뇌졸중 심 포지엄> 성료 국내외 석학들 한 자리에, 뇌졸 중 치료의 의학적 진보 모색 보건복지부 지정, 국내 유 일한 뇌혈관질환 전문병 원으로 선정된 기념으로 명 지성모병원이 <2012 뇌졸 중 심포지엄>을 3월

untitled

Microsoft PowerPoint mD_3-3.ppt

012임수진

γ

일차진료에서고혈압치료 - 맞춤처방 / 선우성 2012 대한임상건강증진학회추계통합학술대회 연수강좌 일차진료에서고혈압치료 - 맞춤처방 선우성울산대학교의과대학서울아산병원가정의학과 Hypertension is a key modifiable risk factor for card

Staging of Lung Cancer


Microsoft PowerPoint - Benefits of CRT-D in CHF.ppt

Microsoft PowerPoint - XUOBWSQUNNWX.pptx

Current Controversies in Blood Pressure Assessment


<31382D322D3420BDC5B1D4C8AF5FB3EDB9AE28C3D6C1BEBABB292E687770>

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있


Microsoft PowerPoint m4_2-1.ppt


서론 대상환자및방법 결과 임상적양상 Table 1. Classification of hypertension in studied patients Classification Number Mild /9099 mmhg 6 Moderate / m

[96_RE11]LMOs(......).HWP

< B3E220C1F6BFAABBE7C8B820C5EBC7D5B0C7C1F5C1F8BBE7BEF720BEC8B3BB28C3D6C1BEC0CEBCE2292E687770>

12이문규

기관고유연구사업결과보고

<BAF1B8B8C3DFB0E8C7D0BCFAB9D7BFACBCF62D E E687770>

< C0D3BBF3B0C7B0AD20C3DFB0E820C7D5B5BFC7D0BCFAB4EBC8B82DC0DBBEF7C1DF2E687770>

Slide 1


Lumbar spine

30대, 신혼의 꿈에 젖어있는 그대에게

YI Ggodme : The Lives and Diseases of Females during the Latter Half of the Joseon Dynasty as Reconstructed with Cases in Yeoksi Manpil (Stray Notes w

주제발표 식품소비구조의변화가국민건강에미치는영향 연구책임자맹원재 ( 자연제 2 분과 ) 공동연구자홍희옥 ( 상명대학교겸임교수 ) - 2 -

<4D F736F F F696E74202D20C7CFC0CCB4DAB8C5B0C5C1F85F B3E23032BFF9C8A35FB1E8BCB1C8F12E >

<C8ADB7C220C5E4C3EBC0E52E687770>

서론 대상및방법 1202 Table 1. Age distribution of 95 adult volunteers Range years Number %

내시경 conference




(Microsoft PowerPoint - PJIOFGQVDOKY.ppt [\310\243\310\257 \270\360\265\345])

<31312EBFF8C8F1B0FC2E687770>


Transcription:

JNC 7 ESH/ESC (Guidelines)

Guidelines 2003. 5 JNC 7 Guidelines ; The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA. 2003;289:2560-2572. 2003. 6 ESH/ESC Guidelines ; 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension* Guidelines Committee** Journal of Hypertension 2003;21:1011-1053. 2003. 11 WHO/ISH Guidelines ; 2003 World Health organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension World Health Organization, International Society of Hypertension Writing Group Journal of Hypertension 2003;21:1983-1992.

(Guideline) Dynasty C.C.

JNC 7 Express Succinct evidencebased recommendations. Published in JAMA May 21, 2003, and as a Government Printing Office publication. Full Report comprehensive justification and rationale.

Why JNC 7? : Purpose

: JNC 6-7 Categorization of hypertension by severity Categroy Systolic Diastolic(mmHg) Optimal < 120 < 80 Normal < 130 <120 and < 85 < 80 High-normal 130-139 or 85-89 Prehypertension 120-139 80-89 Hypertension Stage 1 140-159 or 90-99 Stage 2 160-179 or 100-109 Stage 2 160 or 100 Stage 3 180 or 110 JNC VI JNC VII

: JNC 7 BP Classification Systolic (mmhg) Diastolic (mmhg) Normal < 120 < 80 Prehypertension 120-139 80-89 Stage 1 Hypertension 140-159 90-99 Stage 2 Hypertension 160 100

: ESH/ESC Definitions and classification of blood pressure levels (mmhg)

: WHO/ISH Definitions and classification of blood pressure levels (mmhg) Category Systolic Diastolic Optimal < 120 < 80 Normal 120-129 80-84 High normal 130-139 85-89 Grade 1 hypertension (mild) 140-159 90-99 Subgroup : Borderline 140-149 90-94 Grade 2 hypertension (moderate) 160-179 100-109 Grade 3 hypertension (severe) 180 110 Isolated systolic hypertension 140 > 90 Subgroup : Borderline 140-149

JNC 7 : Key Messages(1) 50 SBP DBP CVD CVD risk 115/75 mmhg 20/10mmHg 2 90% 55 (prehypertension) : 120-139/80-89 mmhg

JNC 7 : Key Messages(2) Thiazide ( ) (compelling indications) : 2 20/10 mmhg 2 : thiazide

JNC 7 : Key Messages(3) = + = + (empathy):

JNC-7 : < 120/80 mmhg 130-139/85-89 mmhg (Prehypertension) : (LSM) 120-139/80-89 mmhg : 2 (stage III II )

JNC-7 (Lifestyle Modification) (DASH diet) 1 6gm (Na 2.4gm, 100mmol) ( 18.5-24.9 kg/m 2 ), ( 30 ) 2 (100% ethanol 30ml ; 720ml, 300ml, 80 90ml ) ( ) 5-20 mmhg/10 kg 8-14 mmhg 2-8 mmhg 4-9 mmhg 2-4 mmhg

JNC-7

JNC-7 Thiazide - ALLHAT - -

JNC-7 20/10 mmhg

JNC-7 : Compelling Indications ACE

JNC-7 3 (Stage 3) -2 160 mmhg 100 mmhg (3 : 180 mmhg 110mmHg) -

JNC-7 (Risk Stratification) - - 120/80 mmhg - : (NIDDM) - +

ESH/ESC Stratification of risk to quantify prognosis

Ten-year risk of fatal cardiovascular disease in populations at low cardiovascular disease risk. Chart based on total cholesterol.

WHO/ISH Stratification of risk to quantify prognosis

JNC-7 /ESH-ESC Cardiovascular Risk Factors and Target Organ Damage(JNC 7) MAJOR RISK FACTORS Hypertension * Cigarette smoking Obesity* (body mass index 30 kg/m 2 ) Physical inactivity Dyslipidemia * Diabetes mellitus * Microalbuminuria or estimated GFR <60 ml/min Age(older than 55 for men, 65 for women) Familly history of premature cardiovascular disease (men under age 55 or women under age 65) TARGET ORGAN DAMAGE Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart failure Brain Storke or transient ischemic attack Chronic Kidney disease Peripheral arterial disease Retinopahty GRF, glomerular filtration ratel. * Components of the metabolic syndrome.

Factors Influencing Prognosis(ESH-ESC) Risk factors for cardiovascular disease used for stratificaton Levels of systolic and diastolic BP Men > 55 years Women > 65 years Smoking Dyslipidaemia (total cholesterol > 250mg/dl * ) or LDL-cholesterol > 155mg/dl * or HDL-cholesterol M < 40, W < 48 mg/dl) Family history or premature cardiovascular disease (at age < 55 years M, < 65 years W) Abdominal obesity (abdominal circumference M 102cm, W 88cm) C-reactive protein 1 mg/dl

Factors influencing prognosis(esh-esc) Target organ damage (TOD) Left ventricular hypertrophy (electrocardiogram: Sokolow-Lyons >38 mm; Cornell > 240 mm*ms; echocardiogram: LVMI M 125, W 110 g/m 2 ) Ultrasound evidence of arterial wall thickening (carotid IMT 0.9 mm) or atherosclerotic plaque Slight increase in serum creatinine ( M 13.-1.5, W 1.2-1.4 mg/dl) Microalbuminuria (30-300 mg/24 h; albumin-creatinine ratio M 22, W 31 mg/g;)

Factors Influencing Prognosis(ESH-ESC) Diabetes mellitus Fasting plasma glucose 126 mg/dl (7.0 mmol/l ) Prostprandial plasma glucose > 198 mg/dl (11.0 mmol/)

Factors Influencing Prognosis(ESH-ESC) Associaged clinical conditions (ACC) Cerebrovascular disease: ischaemic stroke; cerebral haemorrhage; transient ischaemic attack Heart disease: myocardial infarction; angina; coronary revascularization;congestive heart failure Renal disease: diabetic nephropathy; renal impaiment (serum creatinine M >1.5, W > 1.4 mg/dl) proteinuria (>300 mg/24 h) Peripheral vascular disease Advanced retinopathy; haemorrhages or exudates, papilloedema

JNC-7 : <140/90mmHg ( : <130/80mmHg) 1 Thiazide ACEI, ARB, BB, CCB 2 2 thiazide ACEI, ARB, BB, CCB :, ACEI, ARB, BB, CCB

Initiation of Antihypertensive Treatment: ESH-ESC

Choice Between Monotherapy and Combination Therapy ESH-ESC Guidelines

Possible Combinations of Different Classes of Antihypertensive Agents: ESH-ESC Guidelines

JNC 7/ESH-ESC

JNC-7 /ESH-ESC (mmhg) - Normal BP : < 120/80 Optimal BP : < 120/80 - Prehypertension : 120-139/80-89 Normal : 120-129/80-84 High normal : 130-139/85-89 - Stage II = Grade 2 + Grade 3 Hypertension

JNC-7 /ESH-ESC JNC 7 : ESH/ESC : Added risk

JNC-7 /ESH-ESC JNC 7 : Normal < 120/80 mmhg Prehypertension : Stage III Stage II ESH-ESC :,

Patients (%) with BP Controlled Worldwide JNC VI. Arch Intern Med 1997;157:2413 Joffres et al. Am J Hypertens 1997;10:1097 Colhourn et al. J Hypertens 1998;16:747

Patients (%) with BP Controlled Worldwide Chamontin et al. Am J Hypertens 1998;11(6 pt 1):1097 Marques-Vidal and Tuomilehto. J Hum Hypertens 1997;11:213

JNC-7 Message :

: JNC 7 Guidelines Thiazide

ESH-ESC Message :

JNC 7 ESH-ESC Dynasty C.C. Dynasty C.C 3.5Km Dynasty C.C. Dynasty C.C 16Km Dynasty C.C 34Km

FDR

Table I. FDR A Case of Untreated Hypertension YEAR BLOOD PRESSURE COMPLICATIONS TREATMENT (MM HG) 1935 136/78 age 53 1937 162/98 Phenobarbital 1937-1941 170-180/90-100 Low-salt and low-fat diet Massages Digitalis 1941 188/105 Cardiac enlargment Probable lacunar infarcts 1944 186/108 Congestive heart failure (CHF) 1944-1945 180-240/110-130 Renal failure April 12, 1945 cerebral hemorrhage death, age 63 : BP > 300/190 mmhg

1. JNC 7/ ESH-ESC - - 2. guidelines?. 3. guidelines? JNC 7 Guidelines? ESH/ESC Guidelines? WHO/ISH Guidelines?